IO Biotech announced the appointment of Devin Smith as the company's first General Counsel and Chief Compliance Officer. Mr. Smith will oversee all company legal activities and provide strategic guidance and corporate governance. Mr. Smith has more than 25 years of legal and compliance experience serving clients in the life science industries.

Mr. Smith joins IO Biotech from Yumanity Therapeutics, Inc., where he served as Senior Vice President and General Counsel. At Yumanity, he helped lead the sale of the company's neuroscience assets to Johnson & Johnson and a reverse merger with a privately held oncology immunotherapy company. Prior to Yumanity, Mr. Smith served as Senior Vice President and General Counsel of Minerva Neurosciences, Inc., where he was responsible for all legal, governance and compliance matters, and led the sale of potential royalties to Royalty Pharma for upfront and potential milestone payments of $155 million.

Before joining Minerva, Mr. Smith served as General Counsel of Stallergenes Greer plc. Previously, Mr. Smith led the North American legal department for EMD Serono, Inc. Mr. Smith received his J.D. from Suffolk University Law School and his bachelor's degree from the University of North Carolina – Chapel Hill.